The is a tech bubble in the stock market, and it will burst soon. The question is, which of the #NGS companies below will come out stronger from the stock market tech bubble bursting? $ILMN $PACB @nanopore @MGI_BGI
Looking at the NASDAQ for the last 5 years, there was a big drop in March 2020, triggered by the first wave of worldwide #COVID19. The tech bubble was already inflated back then. But the market recovered with a matter of weeks, and kept climbing up.
By 9/8/2020 there was another attempt of a correction, mostly #COVID19 related, but again, with a highly inflated tech bubble, the market recovered and quickly jumped another 1,000 points (around 11,800):
The NASDAQ spent 2 months (and a bit) deciding what to do, fluctuating around the 10-11K mark. This was probably the closest we've seen the tech bubble to burst, but it didn't:
Now to the analysis of each of the #NGS companies:
$ILMN has been going up in the last 5 years, but at a slower pace than the NASDAQ. In fact, in the last 2 years, which are the worst of the tech bubble, $ILMN has been hovering at around $350-400.
If the NASDAQ crashes down from 13,000 to 7,000, $ILMN may go down a bit but retain the $250 mark, maybe even the $300 mark.
Next is $PACB: this is a difficult to predict after the tech bubble bursts, because it spent 2-3 years undervalued (at around the time the Sequel2 came out), but spent the last few months overvalued. The price before the last big NASDAQ correction was around $14-15.
I can't tell if $15 is a good valuation for $PACB after the tech bubble bursts because we haven't had enough time to test any of the valuations between $15 and what it currently is, which is around $35-40 (depending on when you ready this tweet!).
$PACB could hold the $15-20 mark after the tech bubble bursts but a lot will depend on what the company does financially between now and crash: if the have a couple of share issues of $200-300M total, I think they can hold the $20 mark. This may seem counterintuitive,
but for companies with a strong offering and good R&D, raising capital when it's practically free makes you stronger when the bubble bursts. We saw something similar with Google and Yahoo back in the last tech crash (yes, it's been more than 20 years!).
Next in the analysis is @MGI_BGI: here we can't compare them against the NASDAQ because unless I am mistaken, they only trade directly in China (Shenzhen stock market IIRC). So the question is: will they be a stronger or weaker company relative to the other contenders?
My feeling is that they will be relatively unaffected: their biggest rival in #NGS so far is $ILMN, and neither will suffer too much from the tech crash.
Next in the analysis is @nanopore: they've been raising money steadily in the last 2-3 years, seemingly with ease. As an example, when they had to reallocate a big chunk out of Woodford, they did it easily and it wasn't even in the news.
.@nanopore has been charting plans for an IPO for as long as the last 2-3 years, but haven't committed. Why? They don't need to: they've been raising capital without any problems in the last 2-3 years and at decent valuations ($1-2.5B).
We know they feel strongly about the company being bought out by American money one way or another: it's no secret the key people feel strongly about UK companies being sold too quickly to the US. Their investors are well spread, with quite a bit from China/Asia.
So what are their options: 1/ IPO before the tech crash, and profit from the crazy inflation we are seeing in the last 2 years. It's not easy to IPO in the US, as it's tightly regulated, and now actually easier to do in, e.g. Japan or Israel.
But if they do go for a pre-crash IPO, they have a chance to get close to the $10B (or 3-5x the projected current valuation based on past 2-3 raises). Is it crazy to value @nanopore at $10B? Not before the tech crash.
Option 2/ wait for a while, as they have a big inflection point coming from their denser ASICs with voltage squiggles. This may mean the tech bubble bursts before they IPO, which inevitably will mean a correction to the valuation.
But waiting for the voltage-based new ASICs means they are then a threat to *all* the companies in the #NGS market, and all fields, including #LiquidBiopsy. Given that the TAM would be $50-100B, then a post-crash IPO valuation could still range at around $10B.
So that's my opinion on what the #NGS field may look like after a post tech bubble crash. You may be wondering why I am tweeting about this? Well, for one I've been interested in the stock market for the last 22 years. I've traded mostly in tech stocks since then.
I learned a lot about the 2008 financial crisis, more than the first tech bubble (too early for me). I remember buying a lot of $GOOGL for $495 weeks after Lehman's imploded. My flatmate at the time thought I was crazy.
Moreover, I am interested in #NGS (that's why people follow me on @twitter isn't it?) and keen on seeing what other people's opinion is about this: unless I vocally express my opinion, I won't have people's attention on the matter.
Finally, we all like to be correct in our predictions, don't we? I know a tech crash will be another failure of a system that has already had many failures in my lifetime, but I want to make my prediction so that I publish here what I think will happen.
If the tech crash happens tomorrow (it won't, I am not Nostradamus), the sector itself, including biotech, will be smaller than before, which is bad for people in the sector (I include myself here). But the market will be redefined, reshaped, and hopefully wiser than before.
If the tech crash doesn't happen in the next two years, then I will be wrong, and I will have missed an opportunity to put some of my savings to good use: I pulled out of the NASDAQ in April/May 2020. I hope I have a way in soon, and I can continue to invest in tech stock.
Responding to questions (thanks for your replies):
Q: when do I predict the crash will happen?
A: I pulled out in April/May 2020, so I am already wrong by about 8 months! Although to be honest, the 2 months before selling was basically CFDs on $TSLA, so March 2020?
Q: Where would the money depart to? Crypto?
A: It will leave some of the tech tickers for a while, but then go back to it. $GOOGL only became the dominant company that we know today by replacing Yahoo and others post-crash. And I have no opinion on crypto.
Q: There is still a long way to the 2000 tech bubble
A: If true, then there is still a long way for the bubble to burst. But the current NASDAQ includes large established companies like AMZN, AAPL, MSFT, which are going to be unaffected by it. They are buffers in your FT plot.
@d2unroll unroll
If you find the $ILMN analysis missing, there was a disconnect in my twitter thread. It should have connected here:

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Albert Vilella

Albert Vilella Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AlbertVilella

16 Jan
#JPM2021 #BiologicalDynamics @BiodynSD My Highlights: I'll cover this from the point of view of #LiquidBiopsy and #Epigenomics profiling, which is where my interest lies: their next-gen multiomics intro is about exosomes (and EVs, exosomal vesicles?)
The slide about Verita Biomarker Isolation Platform seems to be about isolating cells, with the right-most image showing "Visualized EV", which I presume is exosome vesicles
Later on, they do mention methylation markers, above the exosomes image, so I wonder if it's only DNA inside or bound to the exosomes?
Read 7 tweets
15 Jan
#JPM2021 @GenapSys My Highlights: I think it's fair to say I am more excited than most about this #NGS company, as I see them as an example of how to enter the market while keeping a small profile ($249M raised so far).
They now are aiming at 2021 to ship two new chips: 50MM read chip and 144MM sensor chip (not sure what the difference is between read/sensor).
They show a slide of price per Gb with #Illumina products as a reference, and their products now lined up, I think, for the first time with price per Gb info. Lowest will be the 144MM chip at ~$27/Gb.
Read 14 tweets
14 Jan
#JPM2021 #ExactSciences #LiquidBiopsy My highlights: I will focus on the liquid biopsy / #epigenomics profiling side of the presentation, which is where my interest lies: Exact described the data from Thrive multi-cancer screening, based on 'mutation+protein'
The details they gave on their other recent acquisition, #BaseGenomics are illuminating: they will use their bisulfite-free methylation profiling method for their Cologuard 2.0 test for CRC, but also for the multi-cancer test, and possibly the MRD test as well.
So this means that #ExactSciences intend to upgrade their tech in two steps: from current Cologuard 1.0 to a new test that includes Thrive's tech, and then a second upgrade using the #BaseGenomics #Epigenomics profiling tech.
Read 5 tweets
14 Jan
Some stats and facts about the #Takifugu #rubripes assembly by @genomeark: this is the third iteration of the assembly. The first was completed in 2002. There was another iteration done in 2011. Why was the pufferfish sequenced so early? A lot has got to do with Sydney Brenner...
Indeed, as we can see in this archived version of @ensembl, the Fugu genome was the 5th vertebrate genome to be completed, after human/mouse/rat and zebrafish. Even though zebrafish is widely used as a model organism, Sydney Brenner argued that Fugu was worth sequencing ...
... The reason is that Sydney Brenner was passionate (obsessed?) with gene duplications and functional diversification. I.e. a gene duplicates in two copies, and over time, each copy can specialize in doing something slightly different. ...
Read 8 tweets
13 Jan
#JPM2021 @TwistBioscience My Highlights: back to the #DNAWrite field. TwistBio chip: 1M oligos but only as centralised factory setting.
Expanding to a new factory in Portland (roadmap 2022) to reduce TAT. Also mentioned the "long tail" of Clonal Ready Gene Fragments.
They have a few slides on #DNAasStorage with a denser chip in prototype phase where they think they can archive 1Tb for $100 (pay once, archive forever*) which, if my calculations are correct, would allow for 10-12 years of @awscloud Deep Glacier or similar mth/GB=0.00099*12*1E3
Read 5 tweets
13 Jan
#JPM2021 #LiquidBiopsy notable by their absence, which is more than excusable in these pandemic times: @freenome, Biocartis, Biodesix, Epic Sciences, ArcherDx (not by this name anyway). Worth following developments for them. In my book, worth following #Freenome of the ones here.
Smaller #LiquidBiopsy #Oncology #Diagnostics players also not at #JPM2021 but important in the field: Personalis, Inivata, Exosome Diagnostics, Epigenomics Ag, Personal Genome Diagnostics, Foundation Medicine, Singlera, Cambridge Epigenetix, and Bluestar Genomics.
Now added #BiologicalDynamics to my #LiquidBiopsy list crunchbase.com/organization/b… which displace #Biocept in the #Top30 bit.ly/liqbiop (thanks Kevin Han for the follow).
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!